Key terms
About CUE
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CUE news
Apr 11
11:20am ET
Biotech Alert: Searches spiking for these stocks today
Apr 09
9:35am ET
Cue Biopharma: A Strong Buy on Clinical Breakthroughs and Strategic Financial Positioning
Apr 09
7:35am ET
Oppenheimer Remains a Buy on Cue Biopharma (CUE)
Apr 09
7:07am ET
Cue Biopharma (CUE) Gets a Buy from Stifel Nicolaus
Apr 09
7:06am ET
Cue Biopharma (CUE) Gets a Buy from Piper Sandler
Apr 08
7:05am ET
Options Volatility and Implied Earnings Moves Today, April 08, 2024
Apr 08
7:00am ET
Options Volatility and Implied Earnings Moves This Week, April 08 – April 12, 2024
Apr 03
7:06am ET
Piper Sandler Remains a Buy on Cue Biopharma (CUE)
Mar 13
5:01am ET
Analysts’ Top Healthcare Picks: Cooper Co (COO), Regeneron (REGN)
Mar 13
4:58am ET
Cue Biopharma initiated with a Buy at Jefferies
Feb 29
10:04am ET
Cue Biopharma presenting data on lead clinical asset CUE-101 at symposium
Feb 26
8:10am ET
Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Intellia Therapeutics (NTLA) and Cue Biopharma (CUE)
Feb 20
7:45am ET
Cue Biopharma (CUE) Gets a Buy from Piper Sandler
No recent press releases are available for CUE
CUE Financials
Key terms
Ad Feedback
CUE Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CUE Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range